Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

News Release

MIRA Pharmaceuticals debuts on the Nasdaq with plans to revolutionize medicinal CBD and THC

MIRA Pharmaceuticals

MIRA Pharmaceuticals CEO Erez Aminov, CEO joined Proactive's Stephen Gunnion as the company started trading on the Nasdaq under the ticker symbol 'MIRA'. Aminov said MIRA is making groundbreaking advancements in the cannabis industry with the development of a synthetic marijuana analog that aims to revolutionize medicinal cannabis usage. This new molecular entity, created using patented technology, offers the benefits of THC and CBD without their typical side effects, such as paranoia, anxiety, and impaired cognition. Clinical studies at John Hopkins Medical School revealed that this compound not only alleviates anxiety and chronic pain but also enhances cognition by 100% in animal studies. MIRA's synthetic THC is intended for medicinal use and is undergoing FDA approval. The pharmaceutical-grade version aims to provide a clean, safe, and effective option for patients, allowing them access to cannabis-based relief without the impurities and toxicity associated with plant-based marijuana. Moreover, MIRA's product stands out by being unscheduled, making it available to federal employees and veterans. The company's mission is to address unmet needs, such as anxiety and cognitive impairment in early-stage dementia patients, with minimal side effects. MIRA Pharmaceuticals raised $8.9 million in the IPO, which will be primarily directed towards accelerating toxicology and clinical research to bring the revolutionary drug to market. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

August 03, 2023 02:40 PM Eastern Daylight Time

Video

Stupid Cancer to host CancerCon™ Live in Atlanta, Georgia in August 2023

Stupid Cancer, Inc.

New York, NY - Stupid Cancer, a 501(c)3 nonprofit leader in the adolescent and young adult (AYA) cancer community, announces it will be hosting their annual CancerCon Live at the Omni Hotel at the CNN Center in Atlanta, GA, this summer on August 17–20. CancerCon Live aims to connect AYA cancer patients, survivors, advocates, and health professionals for a weekend filled with inspiring discussions and networking opportunities. “We are excited to bring this event to the southeast to such a young and vibrant city!” says Alison Silberman, CEO of Stupid Cancer. The 2023 agenda is carefully curated to provide the AYA community with valuable resources and many opportunities to connect with your AYA community. Some of this year’s sessions and presenters include… A Community for Caregivers Speaker: Leeann Terwilliger, LCSW, Stupid Cancer I’m Fine: Men, Cancer, and "Cowboy Culture” Speaker: Trevor Maxwell, Man Up to Cancer LOLing through Cancer: Turning your Story into Comedy Speaker: Julia Johns, Comedian Do I Need a Lawyer? Legal Implications of AYA Cancer Speaker: Nicole Jolicoeur, Esq, Triage Cancer Peds to AYA & Long-Term Survivorship Speakers: Sanyukta Janardan, MD, Children's Healthcare of Atlanta/Emory University; Montana Harstad, RN, Emory Healthcare; & James Ludemann, MSN, RN, Children's Healthcare of Atlanta “We're thrilled to have several amazing local experts from Atlanta's renowned medical institutions as session presenters, as well as other survivors and professionals from across the country." says Chelsea Donahue, Director of Programs. For over a decade, Stupid Cancer has brought together hundreds of patients, survivors, caregivers, advocates, and health professionals at the largest gathering of the AYA community - CancerCon. Now gathering both online and off, every CancerCon event is an immersive experience, led by transformative connection and education.The majority of conference attendees are AYA (age 15-39) cancer patients and survivors, but caregivers and health professionals of all ages are also welcome. Beginning in 2022 CancerCon is hosted in a different US city as we seek to make the event always be within reach of our community at all times. About Stupid Cancer: Stupid Cancer's mission is to help empower everyone in the adolescent and young adult (AYA) community by ending isolation and building community. Through innovative programming and strategic communications, the organization aims to provide support, resources, education, and a sense of community both online and in-person. For more information, please visit stupidcancer.org. Contact Details Alison Silberman +1 212-619-1040 media@stupidcancer.org Company Website https://stupidcancer.org/

August 03, 2023 09:51 AM Eastern Daylight Time

Image

xUTILITY to Lead the Way Integrating Research and Patient Care

xCures

xCures, a trailblazer in healthcare technology, is delighted to unveil xUTILITY, a solution poised to transform the patient registry paradigm in the United States. xUTILITY establishes an instantaneous patient registry platform by retrieving records nationwide and automatically digitizing and structuring the electronic health data into a common data model with AI-enhanced abstraction and source verification, as needed. In order to provide a 360-degree view of patient health, xUTILITY includes comprehensive capture capabilities for Electronic Health Records (EHR) and Social Determinants of Health (SDOH) data. "The integration of research and care is the future of healthcare," said Mika Newton, CEO of xCures. "xUTILITY brings this future to the present by delivering rich, comprehensive, and timely patient data. This connectivity will spur personalized, efficient care and groundbreaking medical discoveries." The platform's ability to capture Real-Time, Regulatory-Grade Clinical Data (RRC) is pivotal to delivering quality patient care and pursuing groundbreaking medical research. xUTILITY's distinctive feature is its ability to accommodate user document uploads, integrated with automated data extraction. The resulting synchronized data architecture introduces a new era of research-driven patient care. Its innovative data extraction process, bolstered by a complete data annotation workflow, adheres to 21 CFR Part 11, signifying xCures' unyielding commitment to data integrity. The unprecedented level of automation offered by xUTILITY translates to a remarkable workforce multiplier, with up to a 30-fold improvement in efficiency of data curation. This efficiency enables healthcare organizations to expedite decision-making, improve health outcomes, and enhance operational effectiveness. With xUTILITY, xCures is charting a course toward a future where the integration of research and care forms the backbone of healthcare delivery. About xCures xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. The (unstructured) data is aggregated and organized into a powerful, always up-to-date care summary that helps cancer patients get the right therapy at the right time. The platform's portals, xINFORM for patients and xDECIDE for providers, facilitate treatment option decisions. The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. For more information, contact info@xcures.com or visit http://www.xcures.com. Contact Details xCures Inc Patrick van der Valk pvandervalk@xcures.com Company Website https://xcures.com

August 03, 2023 09:06 AM Eastern Daylight Time

Video

News Release

Innovative Eyewear CEO says company is leading innovation in smart eyewear; unveils new Blueshift Lens

Innovative Eyewear

Innovative Eyewear Inc CEO Harrison Gross joined Proactive's Stephen Gunnion with insights on the company's mission to revolutionize eyewear with smart technology - and news of the launch of the Lucyd Blueshift Lens. Harrison explained that the core product is a pair of smart glasses that seamlessly blend technology with style, enabling users to stay connected while protecting and correcting their vision. These smart glasses function as headphones, offer noise-canceling microphones, and integrate voice assistants like Siri and Google Voice for hands-free convenience. The addition of the Blueshift Lens provides protection against harmful blue light from digital screens. Gross said the recent introduction of ChatGPT integration brings powerful artificial intelligence (AI) capabilities to the glasses, allowing users to access vast amounts of information effortlessly. He also discussed the company's partnership with renowned fashion brands including Nautica, Eddie Bauer and Reebok, highlighting the vision to make smart eyewear a fashionable and accessible accessory. Although still a niche market, the company is optimistic about the smart eyewear market's growth potential. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

August 02, 2023 02:26 PM Eastern Daylight Time

Video

UNOS Plan Reimagines Governance of US Transplant System to Best Serve Patients

United Network for Organ Sharing

United Network for Organ Sharing (UNOS) officially submitted a plan to the Health Resources and Services Administration (HRSA) that would establish a new governance structure for the OPTN in order to strengthen public trust and oversight and accountability. UNOS is the mission-driven, non-profit organization that serves as the nation’s organ donation and transplant system—the Organ Procurement and Transplantation Network (OPTN)— under contract with and overseen by HRSA. The OPTN Independence Plan, which HRSA requested through a contract modification in May 2023, outlines how best to establish an OPTN Board that is legally independent from the OPTN contractor’s board, with no overlap in membership and with distinct obligations. Creating an independent OPTN Board would require the incorporation of the OPTN as an independent, nonprofit organization. The plan represents the culmination of a multi-year effort. UNOS first requested HRSA engagement in May 2021 to create an independent OPTN Board. In January 2023, UNOS sent a follow-up letter to HRSA Administrator Carole Johnson, advocating for a contract modification that would allow UNOS to submit a roadmap detailing concrete steps to advance board independence. “The roadmap that we submitted is a critical step forward for the nation’s organ donation and transplant system and the patients and families who depend on it,” said UNOS CEO Maureen McBride, Ph.D. “Transplant patients will be best served if the OPTN and its Board are given greater independence. Our plan increases accountability, transparency and good governance, which will lead to greater public trust in the national system.” Since the formation of the OPTN, the OPTN and UNOS have used a unitary board approach, where the UNOS Board also serves as the OPTN Board. This has been done in compliance with the National Organ Transplant Act (NOTA), the OPTN Final Rule and the current OPTN contract held by UNOS. Efforts to reform and improve the national system, however, require a collaborative reimagining of this structure. UNOS’ plan will accomplish several critical goals of UNOS, HRSA, Congress and federal partners. It will provide the continuity of services on which patients rely while ensuring the OPTN’s independence from any current or future OPTN contractors. “The OPTN Independence Plan also promotes competition for the upcoming OPTN contract, eliminating any potential or perceived conflict of interest,” UNOS Board President Dianne LaPointe Rudow, APN-BC, DNP, FAAN said. Creating a legally independent OPTN corporation is a key pillar of UNOS’ Action Agenda and was endorsed by the Senate Finance Committee in its August 2022 report. The proposed plan is subject to HRSA approval. “We are committed to working with HRSA to ensure the successful and timely implementation of any OPTN governance restructuring plan by March 31, 2024,” McBride continued. “It is imperative that we pursue reforms as a unified community, and I am proud of the cooperation at all levels that has resulted in this plan.” About UNOS United Network for Organ Sharing (UNOS) is a non-profit, charitable organization that serves as the Organ Procurement and Transplantation Network (OPTN) under contract with the federal government. The OPTN helps create and define organ allocation and distribution policies that make the best use of donated organs. This process involves continuously evaluating new advances and discoveries so policies can be adapted to best serve patients waiting for transplants. All transplant programs and organ procurement organizations throughout the country are OPTN members and are obligated to follow the policies the OPTN creates for allocating organs. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

August 02, 2023 01:50 PM Eastern Daylight Time

Back to School Tips for Healthy Eyes

YourUpdateTV

With the back-to-school season underway, it’s time to take an important look at your child’s eye health. Recently, the President of the American Optometric Association, Dr. Ronald L. Benner, participated in a nationwide satellite media tour to discuss back-to-school eye safety tips and the importance of having in-person, comprehensive eye exams with a doctor of optometry. A video accompanying this announcement is available at: https://youtu.be/_wkZ4uuCvmg Since the pandemic, children have spent more hours using computers and digital devices for remote learning. This increase in screen time can be extremely taxing on the visual system and have long-term consequences for vision and learning. It also increases the likelihood of developing myopia (nearsightedness), eye coordination issues, eyestrain, dry eye, and exacerbated existing eye conditions. Eye and vision disorders can lead to problems in a child’s normal development, school performance, social interactions, engagement in athletics, and self-esteem. Vision disorders that occur in childhood may manifest as problems well into adulthood, affecting an individual’s level of education, employment opportunities, and social interactions. In addition, undiagnosed vision issues are sometimes misdiagnosed as learning disorders. Vision screenings, such as those performed in schools or pediatrician’s offices,are not a substitute for comprehensive eye exams performed by an optometrist. Annual in-person, comprehensive eye exams are one of the most important, preventative ways to preserve vision and overall health. Optometrists are America’s primary eye health care providers, and are on the frontline of eye and vision care. They examine, diagnose, treat and manage diseases and disorders of the eye. In addition to providing eye and vision care, they play a major role in an individual’s overall health and well-being by detecting systemic diseases, such as diabetes and hypertension. Eye exams safeguard overall health by enabling doctors to detect more than 270 serious health conditions including diabetes, high blood pressure, autoimmune diseases and cancers. Eye Deserve More is a multi-faceted national campaign to take a stand that every American deserves in-person comprehensive care from an AOA doctor of optometry as part of their eye health and overall health and wellbeing. As part of the campaign, to further combat serious eye conditions, AOA developed Blink Land, a single-player mobile game that educates gamers through engaging mini-games and interesting trivia to empower them to focus on their eye health. Download Blink Land on Apple App Store and Google Play Store. For more information, visit aoa.org/eyedeservemore About Dr. Benner Ronald L. Benner, O.D., was elected to the American Optometric Association Board of Trustees at the 118th Annual AOA Congress & 45th Annual AOSA Conference: Optometry's Meeting® in June 2015 and elected to the office of President during the 126th Annual AOA Congress & 55th Annual AOSA Conference: Optometry's Meeting in June 2023. In addition to his duties as President, Dr. Benner serves as chair of the Executive Committee, Agenda Committee, and 401(k) Committee. Dr. Benner is also the liaison trustee to the American Academy of Optometry, the AOA Political Action Committee and the National Optometric Leadership Conference. His board assignments also include the Advocacy Committee, the Meetings & Member Experiences Committee, the Faculty & Student Membership Liaisons Committee, the Future Practice Education Task Force and the Advocacy Roundtable Committee. He also serves as a liaison to affiliate associations in Idaho, Illinois, Indiana, Iowa, Michigan and Wisconsin and is the trustee liaison to optometry schools including Chicago College of Optometry, Illinois College of Optometry, Indiana School of Optometry and Michigan College of Optometry—Ferris State University. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

August 01, 2023 10:21 AM Eastern Daylight Time

Video

Doceree collaborates with global marketing experts in an industry-first talk show ‘The Next Marketing with HJ’

Doceree Inc

Doceree, the leading global platform for HCP programmatic marketing, today launches the first season of its brand-new talk show- ‘The Next Marketing with HJ’, a refreshing knowledge-first series for potential and practising pharma marketers. Demystifying the global best practices in healthcare marketing, Doceree aims to provide informative and engaging content to the young marketers in the most candid and intelligible form. The launch of The Next Marketing with HJ series coincides with the rise of unprecedented innovation and competition in the marketing world today. As new-age marketers strive each day to achieve the most from their sought-after and captivating marketing campaigns, the show arrives just in time to provide them with the secrets of successful marketing. Released today on Doceree’s YouTube channel, The Next Marketing with HJ features Harshit Jain MD as the show host, fostering dialogue and knowledge-exchange with global experts who share exceptional insights and experiences from their marketing journeys, engaging in compelling discussions that can potentially captivate young audience and provide a holistic view of the multi-faceted advertising and pharma marketing industry. Harshit Jain being a healthcare innovator himself, has been actively driving transformation across the globe with his life-changing, creative and sustainable marketing ideas. He is a celebrated global marketer, an inspiring entrepreneur, an international speaker, and a published author who recently launched his book ‘ The Next Marketing-To Healthcare Professionals ’. Harshit’s passion for going beyond the creative thresholds and redefining marketing campaigns to augment global healthcare outcomes, makes him the perfect host for the show. Speaking on the launch of the show, Harshit Jain says, “Being interviewed multiple times myself, it fills me with excitement to now sit on the other side. I am extremely excited to exchange experiences with some of the most skilful and seasoned personalities from the healthcare and marketing ecosystem. The brand-new knowledge-exchange series not only promises to deliver empowering conversations around pharmaceutical marketing, but also narrates some extremely interesting untold stories that marketers can relate with and gain greatly from.” As renowned marketing stalwarts from across the world grace the show, Harjot Singh, Global Chief Strategy Officer, McCann Worldgroup, talks about his experience of being on the show and says, “ Shows like this expand our understanding of the industry and provide a unique perspective. I have really enjoyed being part of it.” Another expert, Ritesh Patel, Senior Partner - Global Digital Health, FINN Partners expresses, “ My interaction with Harshit is not only refreshing in terms of knowledge sharing but also insightful for those who want to have an in-depth understanding of pharmaceutical marketing ”. With an interesting content palette--ranging from Creative Innovation in marketing to Digital Literacy and the use of Data & Analytics in advertising, to adoption of Point-of-Care Messaging and Omni-channel Marketing —the show brings to light some new-age tips and tricks for marketers from experts like Nancy Phelan, Omnichannel Activation Lead, Indegene, George C.D Griffith, Executive Vice President-Omnichannel Strategy, Relevate Health, among others. The first episode of the show, featuring Harjot Singh, Global Chief Strategy Officer, McCann Worldgroup, disentangles the dichotomy between ‘Magic & Maths’ and further reveals the value of ‘authenticity’ for brands to stay relevant in today’s digital age. The show takes some hilarious twists with the guest sharing funny anecdotes about their marketing journey, thereby giving the marketers of today an opportunity to witness the industry from an unfiltered lens. Episode 01 I The Next Marketing With HJ: https://youtu.be/frJ4y4CfaNs Show Teaser: https://www.youtube.com/watch?v=ARXWFOu4y64&ab_channel=Doceree About Harshit Jain MD: A marketer, an entrepreneur, and a doctor- Harshit Jain MD, has been working towards introducing creative and innovative ways for pharmaceutical brands to reach Healthcare Professionals globally through his venture Doceree, and has established himself as a successful storyteller and change-maker through creative campaigns- The Immunity Charm, Noon Assembly, Blouse Door, etc. Opening doors into a new world marketing, Jain recently authored a book ‘ The Next Marketing-To Healthcare Professionals’ on Point-of-Care Marketing, and is now ready to build a new home for industry best learnings and conversations on the Future of Marketing through his show- ‘The Next Marketing with HJ'. About Doceree: Doceree is a global platform building unprecedented solutions for healthcare professional (HCP) programmatic marketing with proprietary data tools. It facilitates messaging between life sciences brands and HCPs through an extensive global network of digital endemic and point-of-care platforms to programmatically deliver personalized communications to HCPs and transparent marketing campaign metrics at scale. To learn more, visit www.doceree.com. Contact Details Doceree Inc Tanya Singh +91 70420 89805 tanya.singh@doceree.com Company Website https://doceree.com/us/

August 01, 2023 08:56 AM Eastern Daylight Time

Image

xCures to Contribute Data to Support Aetion®'s Collaboration with FDA

xCures

In a step forward for healthcare research, xCures is pleased to announce that it will support Aetion®'s collaboration with the US Food and Drug Administration (FDA) Oncology Center of Excellence (OCE). As part of this partnership, xCures will provide Aetion with data to support their research collaboration agreement with OCE which centers on using real-world data (RWD) to assess real-world oncology endpoints and measure and address health disparities. As part of the collaboration with OCE, Aetion’s comprehensive fit-for-purpose data assessment identified xCures’ real-time, regulatory-grade data platform to be an appropriate fit for this research study, particularly its ability to integrate clinical data with patient pathology, radiology reports, and imaging assessments. “Aetion is proud to embark on this partnership with xCures to help OCE conduct pivotal research to advance the use of real-world evidence, including in measuring and understanding vulnerable and underrepresented populations,” said Liz Garry, Head of Scientific Research, Aetion. “This work furthers our mission to power critical decisions in healthcare with data science-driven technology and brings us one step closer to achieving health equity.” xCures’ CEO, Mika Newton, explains, "Our platform's automated organization and structuring of aggregated, continuous data result in complete, source-verifiable, and fully longitudinal clinical data sets. This rich dataset can offer unprecedented insight into the real-world patient experience." The contribution of robust RWD from xCures will play an integral role in this endeavor, aiming to fill knowledge gaps and facilitate advancements in healthcare research. For more information about real-time, regulatory-grade clinical data, please visit www.xcures.com/solutions. About Aetion® Aetion is a healthcare analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies. Aetion Evidence Platform® analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs healthcare’s most critical decisions—what works best, for whom, and when—to guide product development, commercialization, and payment innovation. Learn more at aetion.com and follow us on LinkedIn. About xCures xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. The (unstructured) data is aggregated and organized into a powerful, always up-to-date care summary that helps cancer patients get the right therapy at the right time. The platform's portals, xINFORM for patients and xDECIDE for providers, facilitate treatment option decisions. The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. For more information, contact info@xcures.com or visit http://www.xcures.com. Contact Details xCures Inc Patrick van der Valk pvandervalk@xcures.com Company Website https://xcures.com

August 01, 2023 08:45 AM Eastern Daylight Time

Video

Proactive Analyst expects "some good news over the next 1-2 months" from Tiziana Life Sciences

Tiziana Life Sciences PLC

Proactive Research Analyst Robin Davidson talks to Thomas Warner about his new research note on Tiziana Life Sciences Ltd, which focuses on what he expects from the clinical-stage biopharmaceutical company over the next few months. He says Tiziana is approaching a significant milestone with the initiation of a planned study for its lead agent, Foralumab in non-active secondary progressive MS. Meanwhile, data from the existing expanded access protocol study of the same drug is expected to be revealed next month. Additionally, there's a possibility of scientific data being published at what he describes as the "main MS meeting globally" ECTRIMS scheduled to take place in Milan in October. He goes on to say that Foralumab is also in development for other indications, including Alzheimer's disease, where they are seeking grant funding from a philanthropic source to potentially conduct a study in 2024. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

August 01, 2023 08:00 AM Eastern Daylight Time

Video

1 ... 84 85 86 87 88 ... 250